FDA-Drug2025-12-24Class IIICHEMICAL
Somerset Therapeutics cisatracurium besylate injection recalled for subpotent drug strength
LABEL MIX UPNationwide distribution
Stop using Somerset cisatracurium besylate injection
Somerset Therapeutics is recalling cisatracurium besylate injection (200mg/20mL vials, Lot #A250020, expiration 06/30/2026) because stability testing found the drug's strength fell below required standards. This means the medication may not work as intended during medical procedures.
- If you have Lot #A250020 (expiration 06/30/2026), stop using it immediately
- Contact your pharmacy or healthcare facility to confirm whether you have affected vials
- Speak with your doctor or pharmacist about obtaining a replacement supply
Hazard
Subpotent product:out of specification assay results observed during long term stability testing.
Sold states
Nationwide in the USA
Affected count
28,660 20mL vials
Manufactured in
300 Franklin Square Dr, Somerset, NJ, United States
Products
Cisatracurium Besylate Injection USP, 200mg/20mL*(10mg/mL), 10 x 20 mL Single-dose Vials per Carton, Rx Only, Manufactured for: Somerset Therapeutics, LLC, Hollywood, FL 33024, Made in India, Single dose 20mL vial NDC 70069-151-01; 10 x 20 Single dose vials per Carton, NDC 70069-151-10.
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0237-2026Don't want to check this manually?
We email you a Sunday digest of new federal recalls relevant to parents — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.
Get the Sunday Brief